How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Chronic Kidney Disease Market
- By Disease Stage: Stage 1 CKD, Stage 2 CKD, Stage 3 CKD, Stage 4 CKD, Stage 5 CKD (End-Stage Renal Disease)
- By Treatment Type: Conservative Management, Dialysis (Hemodialysis), Dialysis (Peritoneal Dialysis), Kidney Transplantation, Pharmacological Therapy
- By Therapeutic Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Erythropoiesis-Stimulating Agents (ESAs), Phosphate Binders, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
- By End-User: Hospitals, Dialysis Centers, Specialty Clinics, Home Care Settings, Research Institutes
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Stage 1 CKD leads By Disease Stage at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Chronic Kidney Disease Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Disease Stage 5
Treatment Type 5
Therapeutic Class 5
End-User 5
Companies profiled
Fresenius Medical Care AG & Co. KGaA
DaVita Inc.
Baxter International Inc.
Nipro Corporation
B. Braun Melsungen AG
Medtronic plc
AngioDynamics Inc.
Outset Medical Inc.
NxStage Medical
Inc. (a Fresenius Medical Care company)
Asahi Kasei Corporation
Toray Industries Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Fresenius Medical Care AG & Co. KGaA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →DaVita Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →AngioDynamics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Outset Medical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →NxStage Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Inc. (a Fresenius Medical Care company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Asahi Kasei Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Toray Industries Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Gambro (a subsidiary of Baxter International)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Renalytix AI plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →BioPorto Diagnostics A/S
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,009M by 2033 · 7.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Stage 1 CKD39.5
- Stage 2 CKD22.0
- Stage 3 CKD8.5
- Stage 4 CKD8.4
- Stage 5 CKD (End-Stage Renal Disease)21.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,451M → $2,414M · 6.6%
Europe$1,011M → $1,825M · 7.7%
Asia Pacific$923.3M → $1,580M · 6.9%
Latin America$571.6M → $986.1M · 7.1%
Middle East and Africa$439.7M → $730.6M · 6.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.732026
7.742027
7.762028
7.782029
7.782030
7.792031
7.802032
7.832033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Fresenius Medical Care AG & Co. KGaA21.1
- DaVita Inc.17.9
- Baxter International Inc.10.8
- Nipro Corporation8.6
- B. Braun Melsungen AG6.8
- Medtronic plc6.7
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Disease Stage32.1%
Treatment Type11.5%
Therapeutic Class26.7%
End-User29.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.0
- Europe24.2
- Asia Pacific21.0
- Latin America13.1
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Fresenius Medical Care AG & Co. KGaA | 87 | 93 | 78 | 85 | 80 | 81 | 84 |
| DaVita Inc. | 70 | 76 | 74 | 76 | 87 | 82 | 78 |
| Baxter International Inc. | 87 | 82 | 87 | 68 | 71 | 81 | 79 |
| Nipro Corporation | 82 | 80 | 76 | 82 | 62 | 73 | 76 |
| B. Braun Melsungen AG | 63 | 55 | 61 | 73 | 58 | 65 | 63 |
| Medtronic plc | 71 | 51 | 56 | 69 | 67 | 47 | 60 |
| AngioDynamics Inc. | 46 | 52 | 58 | 52 | 61 | 62 | 55 |
| Outset Medical Inc. | 44 | 39 | 42 | 52 | 58 | 53 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Fresenius Medical Care AG & Co. KGaA
- DaVita Inc.
- Baxter International Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Fresenius Medical Care AG & Co. KGaA | ✓ | ✓ | ✓ | ◐ | ◐ | ◐ |
| DaVita Inc. | ◐ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Baxter International Inc. | ✓ | ◐ | ◐ | − | ◐ | ✓ |
| Nipro Corporation | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| B. Braun Melsungen AG | ◐ | ◐ | ◐ | − | ◐ | ◐ |
| Medtronic plc | ✓ | − | − | ◐ | ◐ | ◐ |
| AngioDynamics Inc. | − | − | ◐ | − | − | ◐ |
| Outset Medical Inc. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Fresenius Medical Care AG & Co. KGaA84
2Baxter International Inc.79
3DaVita Inc.78
4Nipro Corporation76
5B. Braun Melsungen AG63
6Medtronic plc60
7AngioDynamics Inc.55
8Outset Medical Inc.48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Fresenius Medical Care AG & Co. KGaADaVita Inc.Baxter International Inc.
Challenger1
Strong scale, closing on the leaders.
Nipro Corporation
Contender2
Focused players with pockets of strength.
B. Braun Melsungen AGMedtronic plc
Niche2
Specialists in a single segment or region.
AngioDynamics Inc.Outset Medical Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disease Stage in North America, then scale across Chronic Kidney Disease Market — a $214M beachhead inside a $3.07B market.
Beachhead (SOM)$214Mobtainable near-term
Serviceable (SAM)$1.22Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Stage 1 CKD
Best fit — highest urgency & budget in Disease Stage.
Economic buyer77 fit
Stage 2 CKD
Strong fit — clear ROI and a fast path to value.
End user65 fit
Stage 3 CKD
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disease Stage in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapeutic Class
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel30%
Digital / self-serve17%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Disease Stage leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Chronic Kidney Disease Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified24%
Evaluation14%
Closed-won6%
$21.1KCAC
$84KLTV
4.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Chronic Kidney Disease Market is a durable-growth opportunity — $2.59B by 2033, compounding at 9.2%.
TAM · 2025$1.28Btoday
TAM · 2033$2.59Bforecast
CAGR9.2%2027–2033
Cumulative$16.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.59BTotal addressable market
SAM$1.05BServiceable available market
SOM$189MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.2% CAGR
Demand compounds through 2033, outpacing GDP across Disease Stage.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disease Stage moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.59BLarge & growingTAM by 2033 at 9.2% CAGR
$1.05BServiceable nowreachable with today’s model
$189MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.02BBear6.0% CAGR
$2.59BBase9.2% CAGR
$3.31BBull12.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Chronic Kidney Disease Market — a $6.17B market by 2033. Plan: grow share from 10.1% to 16.9%.
Market size · 2033$6.17Btotal addressable
Market CAGR7.9%2027–2033
Target share16.9%from 10.1% today
Revenue ambition$1.04Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.1% | 16.9% | On track |
| Revenue | $639M | $1.04B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 35.3% | 40.0% | Ahead |
| Customer retention | 91.3% | 95.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disease Stage
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Type capability
A defensible second engine — invest in Treatment Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disease Stage share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $146M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Type
- Authorise North America expansion plan
- Fund R&D program for Disease Stage leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Chronic Kidney Disease Market conversation — a $3.34B market you can size, segment and defend in minutes.
Market size · 2033$3.34Btotal opportunity
Growth9.6%CAGR to 2033
Addressable buyers1,746+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disease Stage
Goal Grow share in Disease Stage
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 4 mopayback period
$94K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Fresenius Medical Care AG & Co. KGaADaVita Inc.Baxter International Inc.Nipro CorporationB. Braun Melsungen AGMedtronic plcAngioDynamics Inc.Outset Medical Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Chronic Kidney Disease Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Chronic Kidney Disease Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Chronic Liver Disease Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportChronic Lower Back Pain Treatment Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportChronic Lymphocytic Leukemia (CLL) Market
Market size, share, segmentation and regional forecast.
$850M market · 2025 base year
View reportChronic Myelocytic Leukemia Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportChronic Obstructive Pulmonary Disease (Copd) And Asthma Devices Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportChronic Obstructive Pulmonary Disease (Copd) Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportChronic Obstructive Pulmonary Disease (COPD) pharmaceutical Market
Market size, share, segmentation and regional forecast.
$366M market · 2025 base year
View reportChronic Obstructive Pulmonary Disease Devices Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportChronic Obstructive Pulmonary Disorder Drug Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportChronic Plaque Psoriasis Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportChronic Progressive Multiple Sclerosis Market
Market size, share, segmentation and regional forecast.
$876M market · 2025 base year
View reportChronic Pyelonephritis Treatment Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.